DK1259489T3 - Arylfusionerede, azapolycykliske forbindelser - Google Patents

Arylfusionerede, azapolycykliske forbindelser

Info

Publication number
DK1259489T3
DK1259489T3 DK01953630T DK01953630T DK1259489T3 DK 1259489 T3 DK1259489 T3 DK 1259489T3 DK 01953630 T DK01953630 T DK 01953630T DK 01953630 T DK01953630 T DK 01953630T DK 1259489 T3 DK1259489 T3 DK 1259489T3
Authority
DK
Denmark
Prior art keywords
aryl fused
fused azapolycyclic
azapolycyclic compounds
compounds
aryl
Prior art date
Application number
DK01953630T
Other languages
Danish (da)
English (en)
Inventor
P R P Brooks
J W Coe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1259489T3 publication Critical patent/DK1259489T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK01953630T 2000-02-25 2001-02-08 Arylfusionerede, azapolycykliske forbindelser DK1259489T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
DK1259489T3 true DK1259489T3 (da) 2006-10-09

Family

ID=24045406

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01953630T DK1259489T3 (da) 2000-02-25 2001-02-08 Arylfusionerede, azapolycykliske forbindelser
DK05106835.1T DK1619192T3 (da) 2000-02-25 2001-02-08 Arylkondeserede azapolycykliske forbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05106835.1T DK1619192T3 (da) 2000-02-25 2001-02-08 Arylkondeserede azapolycykliske forbindelser

Country Status (40)

Country Link
US (3) US6605610B1 (sl)
EP (2) EP1619192B1 (sl)
JP (1) JP2003524002A (sl)
KR (1) KR100537976B1 (sl)
CN (1) CN1263745C (sl)
AP (1) AP1860A (sl)
AT (2) ATE453643T1 (sl)
AU (2) AU784081B2 (sl)
BG (1) BG65891B1 (sl)
BR (1) BR0108610A (sl)
CA (1) CA2401229C (sl)
CR (1) CR6726A (sl)
CU (1) CU23148A3 (sl)
CY (1) CY1105301T1 (sl)
CZ (1) CZ303203B6 (sl)
DE (2) DE60120366T2 (sl)
DK (2) DK1259489T3 (sl)
DZ (1) DZ3328A1 (sl)
EA (1) EA005316B1 (sl)
EE (1) EE200200475A (sl)
ES (2) ES2263640T3 (sl)
GE (1) GEP20053454B (sl)
HK (1) HK1050894A1 (sl)
HR (1) HRP20020700A2 (sl)
HU (1) HU229482B1 (sl)
IL (2) IL150639A0 (sl)
IS (1) IS2293B (sl)
MA (1) MA26875A1 (sl)
MX (1) MXPA02008311A (sl)
NO (1) NO323608B1 (sl)
NZ (1) NZ519973A (sl)
OA (1) OA12181A (sl)
PL (1) PL365163A1 (sl)
PT (1) PT1259489E (sl)
RS (1) RS51123B (sl)
SI (1) SI1259489T1 (sl)
SK (1) SK12042002A3 (sl)
UA (1) UA74813C2 (sl)
WO (1) WO2001062736A1 (sl)
ZA (1) ZA200206768B (sl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136727A0 (en) * 1997-12-31 2001-06-14 Pfizer Prod Inc Aryl fused azapolycyclic compounds
BR0208992A (pt) * 2001-04-20 2004-04-27 Pfizer Prod Inc Processo para a preparação de indenos 1,3-substituìdos e compostos azapolicìclicos fundidos com arila
SK1912004A3 (en) * 2001-10-31 2004-09-08 Pfizer Prod Inc Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
JP2005528330A (ja) * 2001-11-30 2005-09-22 ファイザー・プロダクツ・インク ５，７，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１）３，５，７，９−ペンタエンの医薬組成物
DE60228478D1 (de) * 2001-11-30 2008-10-02 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
BR0312297A (pt) 2002-07-18 2005-04-12 Cytos Biotechnology Ag Conjugados veìculos de hapteno e seu uso
WO2004037850A2 (en) * 2002-10-22 2004-05-06 Millipore Corporation Multi-sided immersion formation of composite structures and method
RS20050393A (en) * 2002-11-25 2007-12-31 Pfizer Products Inc., Improved process for the preparation of 1,3-substituted indenes
MXPA05007565A (es) * 2003-01-15 2005-09-21 Pfizer Prod Inc Procedimiento mejorado de preparacion de lactamas policiclicas fusionadas con arilos.
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
EP1638971B1 (en) * 2003-06-04 2008-08-20 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianiline with 2,3-dihydroxy-1,4-dioxane
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
PL1677767T3 (pl) 2003-10-14 2011-12-30 Xenoport Inc Krystaliczna postać analogu kwasu gamma-aminomasłowego
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
BRPI0607838A2 (pt) * 2005-02-24 2009-06-13 Pfizer Prod Inc preparação de uma quinoxalina substituìda de pureza elevada
RU2403016C2 (ru) * 2006-04-24 2010-11-10 Пфайзер Продактс Инк. Асимметричные мембраны для устройств доставки лекарственного препарата
AU2007319951A1 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
JP5645217B2 (ja) 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
JP5701607B2 (ja) * 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
BRPI0820668A2 (pt) * 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
WO2010009775A1 (de) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
EP2268639A2 (en) * 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
BRPI1008020A2 (pt) 2009-02-11 2016-03-15 Sunovion Pharmaceuticals Inc antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2010151524A1 (en) * 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
US11266658B2 (en) 2017-03-03 2022-03-08 Ctc Bio, Inc. Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration
EP4084797A4 (en) * 2020-01-03 2024-02-21 Blue Oak Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISEASES
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
IL136727A0 (en) * 1997-12-31 2001-06-14 Pfizer Prod Inc Aryl fused azapolycyclic compounds
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
TR200003122T2 (tr) 1998-04-29 2001-03-21 Pfizer Products Inc Aril bağlı azapolisiklik bileşikler
JP4676062B2 (ja) * 1999-01-29 2011-04-27 アボット・ラボラトリーズ ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式誘導体
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
JP2004532826A (ja) * 2001-03-19 2004-10-28 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ （ｓ，ｒ，ｒ）−（−）−アクチノニンおよびそのアナログの不斉合成、ならびにそれらの使用
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
AU2005234671A1 (en) 2005-12-15
SK12042002A3 (sk) 2004-02-03
EA200200716A1 (ru) 2003-02-27
CU23148A3 (es) 2006-06-29
WO2001062736A1 (en) 2001-08-30
AP1860A (en) 2008-07-02
BG65891B1 (bg) 2010-04-30
AU784081B2 (en) 2006-02-02
YU59602A (sh) 2005-06-10
EP1259489B1 (en) 2006-06-07
AP2002002604A0 (en) 2002-09-30
SI1259489T1 (sl) 2006-10-31
DE60140965D1 (de) 2010-02-11
CA2401229C (en) 2007-10-02
EP1619192A3 (en) 2006-03-22
RS51123B (sr) 2010-10-31
IL150639A (en) 2011-10-31
BG106908A (bg) 2003-04-30
NO20024042D0 (no) 2002-08-23
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
US6605610B1 (en) 2003-08-12
EE200200475A (et) 2003-12-15
EP1259489A1 (en) 2002-11-27
AU2874801A (en) 2001-09-03
ES2263640T3 (es) 2006-12-16
MA26875A1 (fr) 2004-12-20
DE60120366T2 (de) 2007-07-05
CA2401229A1 (en) 2001-08-30
CN1406227A (zh) 2003-03-26
KR20030005209A (ko) 2003-01-17
US20030130260A1 (en) 2003-07-10
HU229482B1 (en) 2014-01-28
DE60120366D1 (de) 2006-07-20
ATE328872T1 (de) 2006-06-15
GEP20053454B (en) 2005-02-25
HUP0204580A2 (hu) 2003-04-28
CZ303203B6 (cs) 2012-05-23
HK1050894A1 (en) 2003-07-11
NO323608B1 (no) 2007-06-18
IS2293B (is) 2007-10-15
IL150639A0 (en) 2003-02-12
EA005316B1 (ru) 2004-12-30
PL365163A1 (en) 2004-12-27
ZA200206768B (en) 2003-09-23
IS6459A (is) 2002-07-05
PT1259489E (pt) 2006-08-31
US7205300B2 (en) 2007-04-17
EP1619192A2 (en) 2006-01-25
UA74813C2 (en) 2006-02-15
KR100537976B1 (ko) 2005-12-21
EP1619192B1 (en) 2009-12-30
CY1105301T1 (el) 2010-03-03
OA12181A (en) 2006-05-09
US7144882B2 (en) 2006-12-05
CZ20022778A3 (cs) 2003-09-17
HRP20020700A2 (en) 2004-12-31
DK1619192T3 (da) 2010-03-29
CR6726A (es) 2003-10-28
MXPA02008311A (es) 2002-12-09
DZ3328A1 (sl) 2001-08-30
AU2005234671B2 (en) 2008-04-17
BR0108610A (pt) 2002-11-19
CN1263745C (zh) 2006-07-12
HUP0204580A3 (en) 2005-04-28
ATE453643T1 (de) 2010-01-15
US20030130261A1 (en) 2003-07-10
JP2003524002A (ja) 2003-08-12
ES2336800T3 (es) 2010-04-16

Similar Documents

Publication Publication Date Title
DK1259489T3 (da) Arylfusionerede, azapolycykliske forbindelser
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
NO20032585D0 (no) ABCA-1 forhöyende forbindelser
IS6971A (is) Ný efnasambönd
DE50213548D1 (de) Substituierte 2-carba-3,5-dicyano-4-aryl-6-aminopylektive liganden
DK1076650T3 (da) Arylfusionerede, azapolycykliske forbindelser
IS6657A (is) Ný efnasambönd
IT250181Y1 (it) Custodia perfezionata per rivoltella
DK1322651T3 (da) Bicykliske, heteroaromatiske forbindelser
AR028220A1 (es) Novedosos compuestos
ATE372338T1 (de) Deshalogenverbindungen
NO20030303L (no) Kalsilytiske forbindelser
NO20031837L (no) Kalsilytiske forbindelser
NO20023508L (no) Kalsilyttiske forbindelser
AR028399A1 (es) Nuevos compuestos
DE60224192D1 (de) Antihaemorrhagische, betain-enthaltende zusammenseuzungen
AR027949A1 (es) Novedosos compuestos
IS8579A (is) Ný efnasambönd
SE0002788D0 (sv) New compounds
SE0003640D0 (sv) New compounds
SE0000263D0 (sv) New compounds
SE0003477D0 (sv) Compounds
SE0001804D0 (sv) New compounds II
SE0000620D0 (sv) Novel compounds
SE0003436D0 (sv) Novel compounds